Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend

Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

In today’s online issue of Cancer, UT Southwestern doctors analyzed data gathered by the National Cancer Institute’s Prostate Cancer Prevention Trial, or PCPT. The trial, which began in October 1993, was designed to test whether finasteride could prevent prostate cancer in men 55 years of age and older. It was stopped early in June 2003 when an analysis showed that finasteride reduced the risk of developing prostate cancer by 25 percent.

UT Southwestern’s analysis of the PCPT data indicates that cost effectiveness and quality of life issues associated with taking the drug are not clear cut, said Dr. Yair Lotan, assistant professor of urology and the Cancer study’s senior author. The PCPT data show that in addition to preventing prostate cancer, finasteride also reduces urinary-tract symptoms associated with benign prostatic hyperplasia. It also decreased sexual desire and caused impotence in 5 percent of the trial participants. Some PCPT participants who did develop prostate cancer also had high-grade tumors, although there is ongoing debate whether this result might have been due to sampling bias.

“Finasteride is currently the only drug that has been shown to prevent prostate cancer in a large randomized trial but is used for this purpose in very few men,” Dr. Lotan said. “A large number of patients are currently taking over-the-counter supplements to prevent prostate cancer, even though there is no scientific evidence to support these products’ claims. It’s important for patients to be aware of this scientific trial and to ask their doctors if finasteride could benefit them.”

In light of all these pros and cons, Dr. Lotan said physicians and patients need to work together closely to weigh how finasteride could affect quality of life on a case-by-case basis.

“With the exception of skin cancer, prostate cancer is the most common cancer in American men,” Dr. Lotan said. “Men who are at low risk for prostate cancer might view taking finasteride as not very cost effective when considering its impact on their quality of life. On the other hand, patients at high risk might see it as cost effective because it lessens their chances of developing prostate cancer.

“Because there is some complexity to the PCPT I think doctors hesitate to discuss its results. While I’m not advocating for the drug, I think physicians should mention finasteride, especially when their patients are asking questions about ways to prevent prostate cancer. Patients should understand and be aware of the proven science that’s out there.”

Source: UT Southwestern Medical Center

Related stories:

Data re-analysis shows drug finasteride reduces risk for most prostate cancers
A re-analysis of data from the landmark Prostate Cancer Prevention Trial (PCPT) finds that finasteride reduces the risk for prostate cancer without boosting the odds of aggressive tumors.
New data show benefit of finasteride in preventing prostate cancer
A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.
What's good for the heart may be good for the prostate
Men who eat a diet low in fat and red meat but high in vegetables and lean protein and who drink alcohol in moderation may not just be doing their hearts a favor. A new study shows that such a heart-healthy diet may also be good for the prostate.
Diet and medications may assist prevention of prostate cancer
Recent investigations of medications, diet and the molecular understanding of prostate cancer are defining potential prevention strategies for the disease, and herald a new stage in the management of this cancer, according to a new review.
Shrinkage of prostate led to overestimation of cancer risk in trial
Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.
Generic prostate drug helps find high-risk cancers early
Men now have another good reason to consider taking finasteride, a well-known generic drug that shrinks an enlarged prostate and reduces the risk of getting prostate cancer by 25 percent. A new study from the Southwest Oncology Group strongly suggests that for men at risk of the disease — which strikes one in six men — finasteride also raises the odds that physicians will find fast-growing prostate cancers early, when they are most easily treatable.
Worried about prostate cancer? Tomato-broccoli combo shown to be effective
A new University of Illinois study shows that tomatoes and broccoli--two vegetables known for their cancer-fighting qualities--are better at shrinking prostate tumors when both are part of the daily diet than when they're eaten alone.
Too much calcium in blood may increase risk of fatal prostate cancer
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.

News discussion:

Medicine & Health news